Tumor neoantigen peptide presented on MHC molecule

Tumor neoantigen peptides presented on major histocompatibility complex (MHC) molecules are short protein fragments generated from somatic mutations unique to cancer cells. These mutations can arise from single nucleotide variants, insertions/deletions, alternative splicing events, or gene fusions. The resulting altered proteins are processed within the tumor cell and loaded onto MHC class I or II molecules. Once displayed on the surface of tumor cells or professional antigen-presenting cells such as dendritic cells, these peptides can be recognized by T cell receptors—primarily those on cytotoxic CD8+ T lymphocytes—triggering a targeted immune response against the cancer. Because they originate exclusively from mutated sequences not found in normal tissues ("non-self"), these antigens tend to be highly immunogenic and less likely to induce central tolerance. This makes them attractive targets for personalized immunotherapies such as therapeutic vaccines and adoptive T cell therapies. The identification and validation process involves next-generation sequencing followed by computational prediction and experimental confirmation that candidate peptides bind strongly to patient-specific MHC alleles. The clinical relevance is underscored by their role in mediating responses—or resistance—to immune checkpoint blockade therapies; tumors with high clonal burden of strong-binding neoantigens tend to respond better than those with heterogeneous or low-abundance presentations. However, challenges include accurately predicting which mutations generate truly immunogenic epitopes and overcoming mechanisms like intratumoral heterogeneity that allow some subclones to evade immune detection. No standard abbreviation exists because "tumor neoantigen" refers broadly to any such mutated peptide presented via an individual's HLA/MHC system rather than a single molecular entity.

Other names

Tumor-specific neoantigenNeoantigen peptideTumor-specific antigenic peptideTSN (Tumor specific neoantigen)

Induction of cytotoxic T lymphocyte response against tumor cells presenting the neoantigen